Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01639846 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis
A Phase 2 study, sponsored by C.T. Development America.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT01639846 is a Phase 2 study that has completed, run by C.T. Development America. The registered enrollment target is 60 participants.
The verdict
NCT01639846, a Phase 2 study, has completed, sponsored by C.T. Development America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
To purpose of this study is to establish the efficacy and safety of RX-10045 ophthalmic solution in alleviating the signs and symptoms of allergic conjunctivitis
Interventions
- DRUG RX-10045
- DRUG Vehicle for RX-10045 arm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-07 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01639846
The ClinicalTrials.gov registry entry for NCT01639846 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is C.T. Development America, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RX-10045 is the first listed.
NCT01639846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01639846 about?
NCT01639846 is a clinical study titled "Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis". To purpose of this study is to establish the efficacy and safety of RX-10045 ophthalmic solution in alleviating the signs and symptoms of allergic conjunctivitis
What is the current status of trial NCT01639846?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2012-07. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01639846?
The interventions under investigation include: RX-10045 (DRUG), Vehicle for RX-10045 arm (DRUG).
Who is sponsoring clinical trial NCT01639846?
This trial is sponsored by C.T. Development America, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.